The Leibniz-Institut für Analytische Wissenschaften - ISAS - e. V. develops efficient analytical methods for health research. Thus, it contributes to the improvement of the prevention, early diagnosis, and therapy of diseases like cardiovascular diseases, autoimmune diseases or cancer. Overall, the institute strives to advance precision medicine by combining knowledge from different fields such as biology, chemistry, pharmacology, physics, and computer science. ISAS is a member of the Leibniz Association and is publicly funded by the Federal Republic of Germany and its federal states.
This position will be to fulfill the work outlined in the consortium project ‘B2B-RARE : Bench to bedside – Mechanisms of rare diseases and personalized treatment', funded by EFRE-NRW. This work will heavily involve the development and implementation of LC-MS based proteomics for small sample inputs, with a focus on extending coverage and sensitivity for proteins within fibroblast samples. In corporation with consortium partners, data generated will be analyzed for a multi-omic approach to analysis, with the goal of implementation of findings into the clinic.
TLNT1_DE